Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Comparison Table: Peptide Classes for Low Testosterone

CJC-1295 / Ipamorelin GHRH + ghrelin mimetic. Stimulates GH release, which upregulates LH and testosterone synthesis CJC: 500 mcg 2×/week; Ipamorelin: 200–300 mcg daily before bed 6–10 weeks for measurable testosterone increase Yes. Does not suppress LH/FSH Fi

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • CJC-1295 / Ipamorelin
  • GHRH + ghrelin mimetic. Stimulates GH release, which upregulates LH and testosterone synthesis
  • CJC: 500 mcg 2×/week; Ipamorelin: 200–300 mcg daily before bed
  • 6–10 weeks for measurable testosterone increase
  • Yes. Does not suppress LH/FSH
  • First-line choice for age-related decline and secondary hypogonadism. Synergistic stacking exploits dual GH pathways.
  • Gonadorelin (GnRH)
  • Direct GnRH analog. Stimulates pituitary LH/FSH release, bypassing hypothalamic signaling
  • 100–150 mcg subcutaneous 2×/day, 12 hours apart
  • 8–12 weeks for normalized testosterone
  • Yes. Directly stimulates gonadal axis
  • Best for secondary hypogonadism with preserved pituitary function. Requires strict pulsatile timing to avoid receptor desensitization.
  • Hexarelin
  • Potent ghrelin mimetic. Amplifies GH pulse amplitude beyond ipamorelin
  • 100–200 mcg daily before bed
  • 4–8 weeks for testosterone response
  • Yes, but chronic use may elevate cortisol and prolactin
  • Stronger GH response than ipamorelin but higher risk of cortisol/prolactin elevation with long-term use (>12 weeks). Reserve for non-responders to CJC/ipamorelin stacks.
  • Kisspeptin-10
  • Upstream GnRH stimulator. Activates kisspeptin receptors in hypothalamus to trigger GnRH secretion
  • 1–10 nmol/kg IV infusion in research settings; practical subcutaneous dosing still under investigation
  • 6–10 weeks
  • Yes. Restores full HPG axis function
  • Emerging research compound. Effective in trials but lacks established subcutaneous dosing protocols. Most useful for hypothalamic amenorrhea rather than male hypogonadism at present.

Related resources

More comparisons